Approval Soon!!! Not If, but WhenStill a buy at these levels, key factors: Very low shares outstanding 88mm, no debt, CEO has 19% of shares and been accumulating last 2-3 years, $2mm cash on hand and warrants to be potentially execised raising new captial of over $12mm. On approval Ketarx will have a huge market to fill currently valued at $2 billion dollars for surgery sadation and pain in hospital settings and clinics around the world. This has been on FDAs drug shortage list since 2018 and is in great demand around the world. Great buying oppotunity at this price...its at least a 10X bagger...Good luck!!!